Expression and clinical significance of chemerin in oral squamous cell carcinoma patients combined with type 2 diabetes

doi:10.19438/j.cjoms.2022.04.013

Abstract

Abstract: PURPOSE: To explore the expression and clinical significance of chemerin in oral squamous cell carcinoma (OSCC) patients with type 2 diabetes (T2DM), analyze the relationship with clinicopathological characteristics and prognosis, in order to provide evidence for further postoperative treatment of OSCC patients with T2DM (T2DM-OSCC). METHODS: OSCC specimens combined with type 2 diabetes and without type 2 diabetes (general OSCC) were selected from the Department of Oral and Maxillofacial Surgery of the Affiliated Hospital of Qingdao University from January 2009 to December 2014. Chemerin expression levels in tumors and para-cancerous tissues were detected by immunohistochemistry (IHC), SPSS 26.0 software package was used for data analysis. RESULTS: In the T2DM-OSCC patients, chemerin expression was significantly higher in tumor tissues compared with para-cancerous tissues (P<0.05) and chemerin expression was associated with cervical lymph node metastasis, higher TNM stage, lower tumor differentiation, and tumor recurrence (P<0.05). Chemerin expression in tumor tissues of T2DM-OSCC patients was significantly higher than that in ordinary OSCC patients (P<0.05). Log-Rank analysis and Kaplan-Meier analysis showed that the 5-year OS was shorter in the group of high chemerin expression combined with type 2 diabetes than other three groups(P<0.05). Cox model showed that chemerin expression in tumor tissues was an independent prognostic factor (P<0.05) affecting OS of T2DM-OSCC patients. CONCLUSIONS: Chemerin expression was higher in T2DM-OSCC patients than in ordinary OSCC, high expression of chemerin suggests poor prognosis in T2DM-OSCC patients. Chemerin is expected to be a potential indicator and target molecule for judging the prognosis of T2DM-OSCC patients.

Key words: Chemerin, Oral squamous cell carcinoma, Type 2 diabetes, T2DM, Prognosis

CLC Number:

R739.8

YANG Song, WANG Ning, ZHAO Shu-chao, LI Heng-yong, GE Sheng-you, ZHOU Kai, SONG Kai, SHANG Wei, FENG Yuan-yong. Expression and clinical significance of chemerin in oral squamous cell carcinoma patients combined with type 2 diabetes[J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(4): 390-395.

References

[1] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[3] 王倩, 侯大为. 口腔鳞状细胞癌发病及转移机制研究进展[J]. 口腔医学研究, 2018, 34(11): 1164-1167.
Wang Q, Hou DW.Research progress in pathogenesis of oral squamous cell carcinoma[J]. Journal of Oral Science Research, 2018, 34(11): 1164-1167.
[4] Yang W, Lu J, Weng J, et al.Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010,362(12):1090-1101.
[5] Scherübl H.Type-2-diabetes and cancer risk[J]. Dtsch Med Wochenschr, 2021, 146(18): 1218-1225.
[6] Ujpál M, Matos O, Bíbok G, et al.Diabetes mellitus and tumors of the oral cavity-epidemiologic correlations[J]. Orv Hetil, 2004, 145(14): 755-759.
[7] Wu CH, Wu TY, Li CC, et al.Impact of diabetes mellitus on the prognosis of patients with oral squamous cell carcinoma: a retrospective cohort study[J]. Ann Surg Oncol, 2010, 17(8): 2175-2183.
[8] Hu X, Xiong H, Chen W, et al.Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: a cohort study with propensity score analyses[J]. Surg Oncol, 2020, 35: 453-459.
[9] Bondue B, Wittamer V, Parmentier M.Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism[J]. Cytokine Growth Factor Rev, 2011, 22(5-6): 331-338.
[10] Del Prete A, Sozio F, Schioppa T, et al.The atypical receptor CCRL2 is essential for lung cancer immune surveillance[J]. Cancer Immunol Res, 2019, 7(11): 1775-1788.
[11] Akgul Balaban Y, Yilmaz N, Kalayci M, et al.Irisin and chemerin levels in patients with type 2 diabetes mellitus[J]. Acta Endocrinol (Buchar), 2019, 15(4): 442-446.
[12] Yamaguchi Y, Du XY, Zhao L, et al.Proteolytic cleavage of chemerin protein is necessary for activation to the active form, Chem157S, which functions as a signaling molecule in glioblastoma[J]. J Biol Chem, 2011, 286(45): 39510-39519.
[13] Tümmler C, Snapkov I, Wickström M, et al.Inhibition of chemerin/CMKLR1 axis in neuroblastoma cells reduces clonogenicity and cell viability in vitro and impairs tumor growth in vivo[J]. Oncotarget, 2017, 8(56): 95135-95151.
[14] Mohr S, Bottin MC, Lannes B, et al.Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells[J]. Biochimie, 2004, 86(1): 13-19.
[15] Xu CH, Yang Y, Wang YC, et al.Prognostic significance of serum chemerin levels in patients with non-small cell lung cancer[J]. Oncotarget, 2017, 8(14): 22483-22489.
[16] Kumar JD, Kandola S, Tiszlavicz L, et al.The role of chemerin and ChemR23 in stimulating the invasion of squamous oesophageal cancer cells[J]. Br J Cancer, 2016, 114(10): 1152-1159.
[17] Ghallab NA, Shaker OG.Serum and salivary levels of chemerin and MMP-9 in oral squamous cell carcinoma and oral premalignant lesions[J]. Clin Oral Investig, 2017, 21(3): 937-947.
[18] Wang N, Wang QJ, Feng YY, et al.Overexpression of chemerin was associated with tumor angiogenesis and poor clinical outcome in squamous cell carcinoma of the oral tongue[J]. Clin Oral Investig, 2014, 18(3): 997-1004.
[19] 尚伟, 郑家伟. 口腔及口咽癌新版TNM分期与NCCN诊治指南部分解读[J]. 中国口腔颌面外科杂志, 2018,16(6):533-546.
Shang W, Zheng JW.Interpretation of the new TNM classification and the NCCN guidelines for cancers of the oral cavity and oropharynx[J]. China Journal of Oral and Maxillofacial Surgery, 2018, 16(6): 533-546.
[20] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4): 292-344.
Diabetes Society of Chinese Medical Association. Chinese guidelines for the prevention and treatment of type 2 diabetes (2017 edition)[J]. Chinese Journal of Practical Internal Medicine, 2018, 38(4): 292-344.
[21] Yu J, Kane S, Wu J, et al.Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer[J]. Clin Cancer Res, 2009, 15(9): 3023-3028.
[22] Kozu Y, Tsuta K, Kohno T, et al.The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma[J]. Lung Cancer, 2011, 73(1): 45-50.
[23] Xiong Y, Bai Y, Leong N, et al.Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies[J]. Diagn Pathol, 2013, 8: 27-35.
[24] Zheng Y, Ley SH, Hu FB.Global aetiology and epidemiology of type 2 diabetes mellitus and its complications[J]. Nat Rev Endocrinol, 2018, 14(2): 88-98.
[25] Ma Q, Li Y, Li P, et al.Research progress in the relationship between type 2 diabetes mellitus and intestinal flora[J]. Biomed Pharmacother, 2019, 117: 109138.
[26] Pearson-Stuttard J, Papadimitriou N, Markozannes G, et al.Type 2 diabetes and cancer: an umbrella review of observational and mendelian randomization studies[J]. Cancer Epidemiol Biomarkers Prev, 2021, 30(6): 1218-1228.
[27] Cowey S, Hardy RW.The metabolic syndrome: a high-risk state for cancer?[J]. Am J Pathol, 2006, 169(5): 1505-1522.
[28] Treeck O, Buechler C, Ortmann O.Chemerin and cancer[J]. Int J Mol Sci, 2019, 20(15): 3750-3765.
[29] 陈亮, 郗爱旗, 阿祥人, 等. 高原久居汉族老年男性血清骨代谢生化指标、Chemerin与缺氧诱导因子1α的变化及相关性[J]. 中国组织工程研究, 2016, 20(33): 4876-4882.
Chen L, Xi AQ, A XR, et al. Changes in serum biomarkers of bone metabolism,Chemerin and hypoxia-inducible factor 1alpha in elderly men living on the plateau[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(33): 4876-4882.
[30] Zhang Z, Wang J, Wang H.Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus[J]. Exp Ther Med, 2018, 15(3): 2936-2940.
[31] Perumalsamy S, Aqilah MZN, Widodo RT, et al.Chemokine like receptor-1 (CMKLR-1) receptor: a potential therapeutic target in management of chemerin induced type 2 diabetes mellitus and cancer[J]. Curr Pharm Des, 2017, 23(25): 3689-3698.
[32] Kumar JD, Holmberg C, Kandola S, et al.Increased expression of chemerin in squamous esophageal cancer myofibroblasts and role in recruitment of mesenchymal stromal cells[J]. PLoS One, 2014, 9(7): e104877.
[33] Lu Z, Liang J, He Q, et al.The serum biomarker chemerin promotes tumorigenesis and metastasis in oral squamous cell carcinoma[J]. Clin Sci (Lond), 2019, 133(5): 681-695.
[34] 陈灵丽, 田文艳, 王颖梅, 等. Chemerin在代谢综合征相关肿瘤治疗中的作用及机制[J]. 现代肿瘤医学, 2020, 28(7): 1198-1201.
Chen LL, Tian WY, Wang YM, et al.The function and mechanism of chemerin in the treatment of metabolic syndrome-associated tumors[J]. Journal of Modern Oncology, 2020, 28(7): 1198-1201.
[35] Hu X, Xiang F, Feng Y, et al.Neutrophils promote tumor progression in oral squamous cell carcinoma by regulating EMT and JAK2/STAT3 signaling through chemerin[J]. Front Oncol, 2022, 12: 812044.
[36] Alkady MM, Abdel-Messeih PL, Nosseir NM.Assessment of serum levels of the adipocytokine chemerin in colorectal cancer patients[J]. J Med Biochem, 2018, 37(3): 313-319.
[37] 杨卫文,黎莉,谭松,等.结直肠癌、结直肠腺瘤患者血清chemerin及粪钙卫蛋白水平检测的临床意义[J].贵州医药, 2011, 35(10): 931-932.
Yang WW, Li L, Tan S, et al.Clinical significance of serum chemerin and fecal calprotectin levels in patients with colorectal cancer and colorectal adenoma[J]. Guizhou Medical Journal, 2011, 35(10): 931-932.